BCIQ Profiles

Company Profile ReportTarget Profile Report
0527 EGFR at ASCO
BioCentury & Getty Images

Targets & Mechanisms

New life for EGFR at ASCO21

ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs

ASCO21 abstracts highlight opportunities for new EGFR-targeting agents and combos to fill holes left by TKIs.

May 29, 2021 | 1:27 AM GMT

This year’s ASCO features a series of compounds and combos taking aim at resistance mechanisms plaguing the sea of marketed therapies against EGFR.

The biggest focus is on EGFR-mutant non-small cell lung cancer (NSCLC), an indication where resistance to EGFR-targeting tyrosine kinase inhibitors (TKIs) frequently emerges, and where patients with certain mutations have historically been left behind.

That picture is rapidly changing for NSCLC with rare EGFR exon 20 insertion mutations, which produce a conformational change in the receptor’s intracellular domain that renders tumors insensitive to traditional TKIs.

This NSCLC subset saw its first approval last week — the bispecific antibody Rybrevant

Read the full 1508 word article

How to gain access

Continue reading with a
two-week free trial.